ClinicalTrials.gg
Active, not recruitingNCT05665751Updated Aug 20, 2024

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

A Phase 2 interventional study of TLC-3595 Dose 1 and TLC-3595 Dose 2 in Insulin Resistance, sponsored by OrsoBio, Inc. Active, not recruiting at 4 sites in New Zealand. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by OrsoBio, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.

Read the detailed description

This is a multicenter, double-blind, randomized study. Participants will be randomized to one of three treatment arms, to receive one of the two doses of TLC-3595 (or matching placebo).

02

Conditions studied

  • Insulin Resistance

Browse trials for

03

In context

Insulin Resistance

2,969 studies on the registry are indexed under Insulin Resistance; 338 are open to participants now.

This study's enrollment of 76 is above the median of 40 across 2,369 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

OrsoBio, Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18-70 years of age, inclusive, at Screening
  • ≥ 28 kg/m2 at Screening
  • Diagnosis of insulin resistance based on HOMA-IR > 2.84 at Screening or a confirmed diagnosis of type 2 diabetes mellitus
  • Screening laboratory evaluations (hematology, chemistry, and urinalysis) must fall within the protocol-defined ranges
  • A 12-lead (ECG) at Screening that is normal or with abnormalities that are considered not by the investigator
  • Female subjects of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 prior to first dose of study drug
  • Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of

Exclusion criteria

Exclusion Criteria:

  • > 10% at Screening
  • Weight loss > 5% weight during the 90 days prior to Screening
  • Pregnant or lactating subjects.
  • Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
  • Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
  • A positive test result for (HIV-1) antibody, (HBV) surface antigen, or (HCV) antibody
  • Unstable cardiovascular disease as defined by any of the following: unstable angina within 6 months prior to Screening; myocardial infarction, coronary artery bypass graft surgery, or coronary angioplasty within 6 months prior to Screening; or cerebrovascular accident within 6 months prior to Screening; obstructive valvular heart disease or hypertrophic cardiomyopathy; congestive heart failure ( Class ≥ 2); implanted defibrillator or pacemaker
  • Medical history of liver disease, including but not limited to, alcoholic liver disease, disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency. A history of nonalcoholic fatty liver disease (NAFLD), including hepatic steatosis or nonalcoholic steatohepatitis (NASH) is permitted.
  • History of intestinal resection or malabsorptive condition that may limit the absorption of study drug
  • Presence of severe peptic ulcer, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions at Screening, in the opinion of the investigator
  • Any scheduled surgery during the trial period, excluding minor surgical procedures performed under local anesthesia, in the opinion of the investigator
  • History of within 5 years prior to Screening except adequately treated carcinoma in situ of the cervix, and/or squamous cell cancer, or other localized non-melanoma skin cancer
  • History of significant drug allergy, such as anaphylaxis or significant drug sensitivity, in the opinion of the investigator
  • Known to study drug, its metabolites, or formulation
  • Presence of any medical condition that could, in the opinion of the investigator, compromise the subject's ability to participate in the study, including a history of substance abuse or a psychiatric disorder, including any subject with a psychiatric hospital admission or emergency room visit in the 2 years prior to Screening
  • Any laboratory abnormality that in the opinion of the investigator could adversely affect the safety of the subject or impair assessment of study results
  • Subjects on any oral medication with a narrow therapeutic window (e.g., warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline, and anticonvulsants)
  • Medications or therapies prescribed or taken over-the-counter for weight loss, in the 90 days prior to Screening.
  • Receipt of vaccination for COVID-19 or any other within 14 days of planned dosing of study drug

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    TLC-3595 Dose 1

    Oral dose of TLC-3595 Dose 1

    Drug: TLC-3595 Dose 1

  • Experimental
    TLC-3595 Dose 2

    Oral dose of TLC-3595 Dose 2

    Drug: TLC-3595 Dose 2

  • Placebo comparator
    Placebo

    Oral dose of placebo-to-match

    Drug: Placebo

Interventions

  • DrugTLC-3595 Dose 1

    Tablets administered orally

  • DrugTLC-3595 Dose 2

    Tablets administered orally

  • DrugPlacebo

    Tablets administered orally

06

What researchers measure

Primary outcomes

  1. Change in insulin sensitivity

    Oral glucose tolerance test will be used to measure insulin sensitivity.

    Time frame: Through study completion, up to Day 84 of the study

  2. Incidence of TLC-3595 treatment-emergent adverse events

    Adverse events (AEs) - severity of the AEs will be graded using the Common Terminology Criteria for AE (CTCAE) (v5.0). The relationship between AEs and the study drug will be indicated as related or not related.

    Time frame: Through study completion, up to Day 84 of the study

07

Study locations

4 sites
  • OrsoBio Research Site
    Auckland, 0626, New Zealand
  • OrsoBio Reseach Site
    Auckland, 1010, New Zealand
  • OrsoBio Research Site
    Auckland, 1010, New Zealand
  • OrsoBio Research Site
    Christchurch, 8011, New Zealand
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05665751
Lead sponsor
OrsoBio, Inc
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Mar 8, 2023
Primary completion
Sep 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 20, 2024

Study contacts

OrsoBio Study Director
study director · OrsoBio, Inc

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion